Document is current
Any future updates will be listed below
-
Authors
Lin, Yi-Ting https://orcid.org/0000-0002-5833-0040
Sayols-Baixeras, Sergi https://orcid.org/0000-0002-1181-6262
Baldanzi, Gabriel https://orcid.org/0000-0003-3962-3953
Dekkers, Koen F. https://orcid.org/0000-0002-4074-7235
Hammar, Ulf
Nguyen, Diem https://orcid.org/0000-0002-9680-5772
Nielsen, Nynne https://orcid.org/0009-0003-5603-3514
Eklund, Aron C. https://orcid.org/0000-0003-0861-1001
Varotsis, Georgios https://orcid.org/0000-0002-3320-2448
Holm, Jacob B. https://orcid.org/0000-0003-1756-0875
Nielsen, H. Bjørn https://orcid.org/0000-0003-2281-5713
Lind, Lars
Bergström, Göran https://orcid.org/0000-0003-4289-5722
Smith, J. Gustav
Engström, Gunnar
Ärnlöv, Johan
Sundström, Johan https://orcid.org/0000-0003-2247-8454
Orho-Melander, Marju https://orcid.org/0000-0002-3578-2503
Fall, Tove https://orcid.org/0000-0003-2071-5866
- License Information
-
More Information
Article History
Received: 13 March 2024
Accepted: 17 June 2025
First Online: 7 July 2025
Competing interests
: The authors declare the following competing interests: N.N., A.C.E. and J.B.H., and H.B.N. are employees of Cmbio. The funders had no role in study design, data collection and analysis, decision to publish, nor preparation of the manuscript. J.Ä. has received lecture fees from Novartis and AstraZeneca, and served on advisory boards for AstraZeneca and Boerhinger Ingelheim, all unrelated to the present paper. J.S. reports stock ownership in Anagram kommunikation AB and Symptoms Europe AB, unrelated to the present study. All other authors declare no conflicts of interest in connection with this study.
